- Home
- SCNX vs SCYX Comparison
SCNX vs SCYX Comparison
Compare SCNX & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- SCYX
- Stock Information
- Founded
- SCNX 2010
- SCYX 1999
- Country
- SCNX United States
- SCYX United States
- Employees
- SCNX N/A
- SCYX N/A
- Industry
- SCNX Other Pharmaceuticals
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- SCYX Health Care
- Exchange
- SCNX Nasdaq
- SCYX Nasdaq
- Market Cap
- SCNX 33.6M
- SCYX 36.8M
- IPO Year
- SCNX 2020
- SCYX 2014
- Fundamental
- Price
- SCNX $0.90
- SCYX $0.86
- Analyst Decision
- SCNX
- SCYX
- Analyst Count
- SCNX 0
- SCYX 0
- Target Price
- SCNX N/A
- SCYX N/A
- AVG Volume (30 Days)
- SCNX 76.0K
- SCYX 204.8K
- Earning Date
- SCNX 05-12-2025
- SCYX 05-15-2025
- Dividend Yield
- SCNX N/A
- SCYX N/A
- EPS Growth
- SCNX N/A
- SCYX N/A
- EPS
- SCNX N/A
- SCYX N/A
- Revenue
- SCNX $146,901.00
- SCYX $2,630,000.00
- Revenue This Year
- SCNX N/A
- SCYX $460.12
- Revenue Next Year
- SCNX N/A
- SCYX $253.87
- P/E Ratio
- SCNX N/A
- SCYX N/A
- Revenue Growth
- SCNX N/A
- SCYX N/A
- 52 Week Low
- SCNX $0.69
- SCYX $0.72
- 52 Week High
- SCNX $23.77
- SCYX $2.60
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- SCYX 47.45
- Support Level
- SCNX N/A
- SCYX $0.85
- Resistance Level
- SCNX N/A
- SCYX $1.02
- Average True Range (ATR)
- SCNX 0.00
- SCYX 0.08
- MACD
- SCNX 0.00
- SCYX 0.00
- Stochastic Oscillator
- SCNX 0.00
- SCYX 46.97
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.